title: [Pamidronate in treatment of pain caused by bone metastasis].
abstract: OBJECTIVE
  Clinical studies showed that pamidronate has curative effects on pain induced by bone metastasis. This study was to observe curative effects, and side effects of different dosages of pamidronate on pain induced by bone metastasis.
  
  
  METHODS
  Ninety patients with metastatic bone tumor were divided into 2 groups randomly. In group A, 120 mg pamidronate was given by intravenous infusion in 3 days (60 mg day(1), 30 mg day(2-3)); in group B, 90 mg pamidronate was given by intravenous infusion in 3 days (30 mg day(1-3)), repeated every 4 weeks.
  
  
  RESULTS
  The notable effect, effect, and no effect were observed in 20, 23, and 2 patients of group A, and 16, 20, and 9 patients of group B, respectively. Total effective rate in group A was 95.6%(43/45) , in group B was 80.0% (36/45) (P< 0.05). Curative rate within 1 course of treatment in group A was 88.9% (40/45), in group B was 57.8% (26/45) (P< 0.01). Curative rate within 1 week in group A was 80% (36/45) , in group B was 57.8% (26/45) (P< 0.05). Side effects were observed in 3 patients (6.7%).
  
  
  CONCLUSIONS
  Pamidronate has good curative effects in treating pain induced by bone metastasis. Efficacy of 120 mg pamidronate is better than 90 mg pamidronate.
authors.affiliation: Department of Medical Oncology, Jiangxi Provincial Cancer Hospital, Nanchang, Jiangxi, 330029, P.R.China. wangdijin@hotmail.com
authors.forename: Di-Jin
authors.initials: DJ
authors.lastname: Wang
authors.forename: Hui-Qun
authors.initials: HQ
authors.lastname: Liu
authors.forename: Jian
authors.initials: J
authors.lastname: Ren
authors.forename: Ying-Lan
authors.initials: YL
authors.lastname: Chen
authors.forename: Qin-Yuan
authors.initials: QY
authors.lastname: Zhan
authors.forename: Yun
authors.initials: Y
authors.lastname: Cai
authors.forename: Min-Zhi
authors.initials: MZ
authors.lastname: Liu
mesh_terms: D000328:Adult; D000368:Aged; D001859:Bone Neoplasms / Q000503:physiopathology* / Q000556:secondary*; D001943:Breast Neoplasms / Q000473:pathology; D004164:Diphosphonates / Q000008:administration & dosage / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D005260:Female; D005334:Fever / Q000139:chemically induced; D006801:Humans; D007262:Infusions, Intravenous; D008175:Lung Neoplasms / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D010146:Pain / Q000188:drug therapy* / Q000209:etiology; D000077268:Pamidronate; D013274:Stomach Neoplasms / Q000473:pathology
chemical_list: D004164:Diphosphonates; D000077268:Pamidronate